The Headline: An updated analysis! of the landmark phase 3 CROWN trial demonstrates, of the roughly two-thirds of patients who remain free from progression in the first two years on lorlatinib for metastatic ALK-rearranged non-small cell lung cancer, an amazing 79% continue to remain without evidence of progression at 7 years. | Mok, ASCO 2026
